相似文献
1
Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy.
Br J Clin Pharmacol. 2006 Jul;62(1):27-34. doi: 10.1111/j.1365-2125.2006.02714.x.
2
Pharmacology and pharmacogenetics of chemotherapeutic agents.
Cancer Invest. 2009 Jun;27(5):482-8. doi: 10.1080/07357900802574660.
3
The role of pharmacogenetics in chemotherapy: modulation of tumour response and host toxicity.
Cancer Surv. 1993;17:79-104.
4
Pharmacogenetics of cytotoxic drugs.
Expert Rev Anticancer Ther. 2001 Aug;1(2):301-8. doi: 10.1586/14737140.1.2.301.
5
Pharmacoproteomics in drug development.
Pharmacogenomics J. 2003;3(2):69-76. doi: 10.1038/sj.tpj.6500164.
6
Factors involved in clinical pharmacology variability in oncology (review).
Anticancer Res. 1994 Nov-Dec;14(6A):2269-72.
7
Recent advances in the pharmacogenetics of cancer chemotherapy.
Curr Opin Mol Ther. 2002 Dec;4(6):565-71.
8
Overview of recent topics in clinical pharmacology of anticancer agents.
Cancer Chemother Pharmacol. 1998;42 Suppl:S22-30. doi: 10.1007/s002800051076.
9
[Differentiating the activity of anticancer drugs: the role of transcription factors].
Ann Pharm Fr. 1998;56(1):1-8.
10
Using genetic variation to optimize cancer chemotherapy.
Clin Adv Hematol Oncol. 2003 Feb;1(2):107-11.
引用本文的文献
1
Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms.
Br J Clin Pharmacol. 2006 Jul;62(1):1-4. doi: 10.1111/j.1365-2125.2006.02721.x.
本文引用的文献
1
Positron-emission tomography and assessment of cancer therapy.
N Engl J Med. 2006 Feb 2;354(5):496-507. doi: 10.1056/NEJMra050276.
2
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
Cancer Chemother Pharmacol. 2006 Apr;57(4):427-35. doi: 10.1007/s00280-005-0035-2. Epub 2005 Dec 2.
3
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
Clin Cancer Res. 2005 Nov 15;11(22):8097-104. doi: 10.1158/1078-0432.CCR-05-1152.
4
The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer.
Cancer Treat Rev. 2005 Dec;31(8):603-17. doi: 10.1016/j.ctrv.2005.09.006. Epub 2005 Nov 17.
5
Simultaneous determination of capecitabine and its metabolites by HPLC and mass spectrometry for preclinical and clinical studies.
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Nov 5;826(1-2):232-7. doi: 10.1016/j.jchromb.2005.09.010. Epub 2005 Sep 28.
6
Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study.
Clin Cancer Res. 2005 Aug 15;11(16):5893-9. doi: 10.1158/1078-0432.CCR-04-2546.
7
Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
J Clin Oncol. 2005 Aug 20;23(24):5552-9. doi: 10.1200/JCO.2005.06.208.
8
Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.
J Clin Oncol. 2005 Sep 1;23(25):6117-25. doi: 10.1200/JCO.2005.06.075. Epub 2005 Aug 8.
9
Identifying DNA methylation biomarkers of cancer drug response.
Am J Pharmacogenomics. 2005;5(4):223-32. doi: 10.2165/00129785-200505040-00003.
10
An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers.
Proc Natl Acad Sci U S A. 2005 Jul 12;102(28):9901-6. doi: 10.1073/pnas.0500756102. Epub 2005 Jul 5.
Zotero 插件